A Comprehensive Overview of Coumarinyl-Triazole Hybrids as Anticancer Agents

There are over 100 commercially available drugs for the handling of cancer, but only a handful of them have high specificity, leading to a variety of side effects. The past few decades have seen the scientific community concentrate on drug discovery. Candidates that are pharmaceutically active are isolated from natural resources and then synthesized. More than 60% of medications in the market are synthesized with natural components. Additionally, necessity for pharmaceutical therapies is critical due to the prevalence of chemoresistance and relapse. Coumarin is a highly privileged pharmacophore for the creation of drugs for the medications of cancer because coumarin-derived compounds are widely distributed in wildlife and can easily interplay with a variety of enzymes and targets on the receptors site in cancer affected cells through interactions with weak bond. Conversely, triazole also known as pyrrodiazole is part of numerous clinically and medically used drugs for the treatment of several diseases, for instance, diabetes, cancer, etc, and a number of 1,2,3-triazole by-products are currently being tested in clinical trials to treat various types of cancers. Consequently, the goal of this review is to highlight significant coumarin analogues with triazole moiety as anticancer properties wrapping the articles published from 2012-2022.